First Alzheimer's blood test available in US in June
The first blood test to help diagnose Alzheimer's disease will be available from late June in the US. PHOTO: ISTOCKPHOTO
WASHINGTON – The first blood test to help diagnose Alzheimer's disease will be available from late June in the US following regulatory clearance for its use last week, according to the Japanese company behind the innovation.
The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer's disease, Mr Goki Ishikawa, head of Fujirebio Holdings Inc., a unit of Japan's H.U. Group Holdings Inc., said in an interview on May 20. It's partnering with bigger rivals like Beckman Coulter Inc. to help develop and manufacture their products, he said.
The Food and Drug Administration cleared the blood test to help diagnose Alzheimer's disease last week, potentially making it easier to find and treat patients with the memory-robbing disease that affects nearly seven million Americans.
The test was cleared for use in people at least 55 years old and who exhibit signs of the disease. It is designed to detect amyloid, a protein that can build up in the brain and is a hallmark of Alzheimer's, the most common form of dementia in the elderly.
The process, which takes roughly 30 minutes from drawing the blood to diagnosis, will be available to patients at a fraction of the cost of a PET scan. The method is viewed as a critical step in making new types of Alzheimer's treatments widely accessible.
Until now, patients typically have to get a specialised PET scan to detect amyloid in their brains or undergo cerebrospinal fluid tests, both of which are more expensive and invasive. The lack of quick and easy tests has until now slowed the rollout of new Alzheimer's drugs like Eisai Co. and Biogen Inc.'s Leqembi and Eli Lilly & Co.'s Kisunla.
The company plans to file data to seek approvals in Japan as early as August and Europe within this year, Mr Ishikawa said. In China, Fujirebio's undisclosed partner will probably submit data to regulators next year, he added. In India, it partners with Agappe Diagnostics Ltd.
'We have a presence in Japan but that's not necessarily the case in markets overseas,' said Mr Ishikawa. 'We can't get the market shares by ourselves, but if we supply the raw materials to partners, we can benefit through them.' BLOOMBERG
Join ST's Telegram channel and get the latest breaking news delivered to you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
5 hours ago
- Straits Times
Trump's cuts are ‘devastating' for vulnerable women worldwide: UN
The withdrawal of the US from the funding arena for reproductive health has been devastating, said UNFPA chief Natalia Kanen. PHOTO: AFP NEW YORK - The United Nations Population Fund (UNFPA) has faced budget cuts before, but the impact of US President Donald Trump's policies has been even more 'devastating' for reproductive health worldwide, chief Natalia Kanem told AFP. The agency has been targeted by US conservatives since the Kemp-Kasten Amendment's enactment in 1985 by Congress, when the administration of then president Ronald Reagan rallied against China's population policies, accusing Beijing of promoting forced abortions and sterilisations. All subsequent Republican presidencies have cut US funding to UNFPA, and the second Trump administration is no exception. 'We've had over US$330 million (S$424.78 million) worth of projects ended,' virtually overnight, in 'some of the hardest hit regions of the world' like Afghanistan, Ms Kanem said in an interview coinciding with the release of the UNFPA's annual report on June 10. 'So yes, we are suffering.' Ms Kanem pointed to the Zaatari refugee camp in Jordan as an example, where over the years more than 18,000 pregnancies were delivered by 'heroic midwives' who 'conducted these over 18,000 deliveries without a single maternal death, which you know, in a crisis situation is extraordinary.' 'Those maternity wards today have closed. The funding cuts immediately have meant that those midwives are no longer able to do their jobs,' Ms Kanem said. Although it is too soon to estimate the precise impacts of the US cuts, they will inevitably result in increased maternal mortality and more unintended pregnancies, according to Ms Kanem. 'What's different this time for UNFPA is that our ecosystem of other reproductive health actors who might be able to fill in for us,' Ms Kanem said, adding they are 'reeling from huge impact of having their funding denied.' The Trump administration has slashed many such external aid programmes. 'So it is very lamentable that this year, to me, has been drastically worse than ever before, precisely because now everybody is caught up in the whirlwind.' 'The withdrawal of the United States from the funding arena for reproductive health has been devastating,' Ms Kanem said. Desire and rights American policy is not only marked by funding cuts, but also a challenge to gender equality matters. 'There will be debates about concepts, but there shouldn't be any debate about the non-negotiability of the rights and choices of women and adolescent girls,' Ms Kanem emphasised. 'We always embrace change, but we should not compromise on these common values which spell the difference between life and death for women and girls all around the world,' she continued. 'Women deserve support. Adolescent girls deserve to finish their schooling, not become pregnant, not be bartered or sent off into marriage as a non-solution to issues that families may face.' The UNFPA's annual report, published on June 10 and based on the results of a survey of 14,000 people from 14 countries – nations which represent over a third of the world's population – also underscores concerns that millions of people around the world cannot create the families they desire. More than 40 per cent of those over the age of 50 reported not having the number of children they wanted – with 31 per cent saying they had fewer kids than they desired and 12 per cent saying they had more than they wanted. More than half of respondents said economic barriers prevented them from having more children. Conversely, one in five said they were pressured into having a child, and one in three adults reported an unintended pregnancy. The majority of people 'live in countries where fertility rates have fallen so far and so fast that they are below replacement,' Ms Kanem said. 'We know that the issue of population pressure takes almost like a headline drastic view. Some people think there are way too many people. Others are saying we don't have enough, women should have more babies,' Ms Kanem said. 'What UNFPA really cares about is a woman's true desire, rights and choices,' she said. AFP Join ST's Telegram channel and get the latest breaking news delivered to you.
New Paper
7 hours ago
- New Paper
Newborn with 'bubble boy disease' now thriving, thanks to Singapore's early detection programme
Mannat Singh was only six days old when he was diagnosed with severe combined immunodeficiency (SCID). This means he was born without a functioning immune system, making him highly vulnerable to even the common flu. Without treatment, Mannat would not have made it past his first birthday. His mother Harminder Kaur, 39, a nurse, recalled the guilt and fear she felt "because I made him this way". SCID is a rare life-threatening genetic disorder that affects one in 50,000 babies worldwide, with one new case born in Singapore every two years. "It did not help our state of mind when his odds were stacked against him," said her husband Harminder Singh, 39, an IT consultant. It is also known as "bubble boy disease" after David Vetter, an American boy with the disease who captured the world's attention for living all his life in a sterile plastic enclosure - his "bubble". At the time of his birth in 1971, a bone marrow transplant from an exact matched donor was the only cure for SCID, but there was no match available in David's family. In 1984, four months after receiving a bone marrow transfusion via a new technique, the 12-year-old died from lymphoma, a cancer later traced to a dormant Epstein-Barr virus in the donor bone marrow. As for baby Mannat, he had Artemis SCID, a rare form of recessive radiosensitive SCID, which meant he could not be treated with radiation or have certain scans done. Mannat Singh was born without a functioning immune system, making him highly vulnerable to even the common flu. ST PHOTO: NG SOR LUAN Memories of what the couple went through with their younger son brought tears to Mr Singh, who said: "We were prepared to do whatever we could to give Mannat the best chance at life. We took a step at a time, discussing putting him on chemotherapy and deferring to the experts." Fortunately for Mannat, his condition was picked up at KK Women's and Children's Hospital (KKH) through the National Expanded Newborn Screening (Nens) programme. The programme, which started in 2006 with the aim of screening all babies born in Singapore for metabolic and heritable diseases, was expanded in 2019 to include five other treatable serious childhood-onset conditions such as SCID and cystic fibrosis. In 2024, all newborns at KKH were screened under Nens, while the national screening rate in Singapore is 96 per cent. This involves pricking the baby's heels to collect a blood sample between 24 and 72 hours after birth. Screening for SCID involves checking the baby's blood for DNA fragments called T-cell receptor excision circles (Trecs), which show that the immune system is making T-cells properly, said KKH geneticist Ting Teck Wah. The test does not confirm an SCID diagnosis, but abnormalities such as low or absent Trecs signal that the baby needs to go through more testing, he said. After screening almost 178,000 babies since 2019, Nens has picked up two babies positive for SCID, Dr Ting added. Dr Bianca Chan, a consultant with the rheumatology and immunology service at KKH, said the only real curative treatment for SCID is a bone marrow transplant from a healthy donor. Stem cells from the bone marrow of a healthy donor can develop into infection-fighting T-cells, helping babies with SCID build a functioning immune system. "The highest success is when it is performed within the first three to four months of life, before the baby develops significant infections. This makes SCID screening at birth crucial for early diagnosis to actively prevent infection," she said. Dr Chan added that if the baby has an active infection before the transplant, its survival rate even with a transplant is only 50 per cent, "because it becomes very, very difficult to have a successful transplant". Mannat Singh and parents Harminder Kaur and Harminder Singh, with KKH doctors (back row, from left) Michaela Seng, Ting Teck Wah and Bianca Chan. ST PHOTO: NG SOR LUAN Dr Michaela Seng, a senior consultant with the haematology and oncology service at the hospital, said a programme is immediately put in place to protect the child from infections before doctors prepare for donor selection. "We meet the parents to explain the implications of the diagnosis and tell them they are typically appropriately suitable as potential donors. We also go through the process of harvesting and processing the donor stem cells, and the lab then receives these stem cells... and prepares small bags of what we call memory T-cells that help fight infection," she said. "During this time, the baby is admitted to the transplant unit and undergoes complete isolation. For seven days, he is given conditioning therapy, which is chemotherapy that is tailored to the size and the weight of the baby, to allow us to clear unnecessary cells that would prevent successful engraftment of the donor stem cells. The donor cells are then infused, and we wait for the transplant to take effect," she added. Mannat became the first newborn in Singapore to have his SCID diagnosed at birth, and the first to receive a stem cell transplant - from his mother's bone marrow - before the symptoms emerged. Today, at 19 months, Mannat is healthy and asserting himself with his parents and older brother Birakaal, aged four. "I feel now that life has returned to normal and we have put the past behind us. We are now looking forward to having the boys grow up healthy and happy," Ms Kaur said.
Business Times
20 hours ago
- Business Times
Asia healthcare assets risk overvaluation as private investors scoop them up
[SINGAPORE] As private equity (PE) investors pour money into Asian healthcare, some observers are concerned that this sector could soon overheat. Some recent deals this year include KKR's US$400 million purchase of a 54 per cent stake in India's Healthcare Global Enterprises in February. In Singapore, another American PE firm TPG took Catalist-listed nursing operator Econ Healthcare private in a deal worth nearly S$88 million. When the proposed transaction was announced in February, the offer price represented a 20 per cent premium to Econ's last traded share price on Jan 14. 'We are not the only ones to see the opportunity of healthcare in Asia, and, as a consequence, valuations can be high,' Abrar Mir, co-founder and managing partner of healthcare-focused PE firm Quadria Capital, told The Business Times. Other factors driving investors to the healthcare sector – perceived as defensive, and so able to withstand the ups and downs of economic cycles – is the ongoing macroeconomic uncertainty and volatility in global financial markets. This is particularly so in Asia, where investors have been diversifying away from China in the last few years, to avoid being caught in the cross hairs of the nation's tensions with the United States. As PE firms and their investors focus on acquiring companies independent of China, more deals have been transacted in Japan, South Korea and India, where the demand for healthcare and related services is strong and largely unaffected by tariffs. 'Japan has always been a stable healthcare market, and particularly because of (its) demographics and medical needs,' said David Braga Malta, thematic health principal at Pictet Alternative Advisors, to BT. 'We saw some of the mid-sized Japanese pharma companies being very acquisitive in the recent months and years... And of course, we saw the boom in the IPO (initial public offering) markets in India last year.' BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Asia's appeal even drew European PE investors to buy South Korean assets for the first time in 2024, he added. Last September, France's Archimed spent US$742 million buying Jeisys Medical, a South Korean developer of aesthetic medicine devices. Like shopping in Louis Vuitton 'One of the key things that I always say to my investors is that... investing in healthcare in Asia is like shopping in Louis Vuitton. So, as an investor, we have to navigate that, be careful not to overpay,' said Quadria Capital's Mir. According to a Bain & Co report, global PE deal value in the sector surged last year to an estimated US$115 billion – the second highest on record. Bain added that PE firms continue to invest in healthcare in the Asia-Pacific, where deal values have been steadily rising since 2016. Industry participants named India as the country attracting the most number of healthcare PE investors. An ageing population, rising incidence of chronic disease and growing awareness of preventive care, combined with the opening up of its insurance market to foreign investment, are making India stand out. Bain estimated that the country made up 26 per cent of the 62 deals transacted in the Asia-Pacific last year. PwC said its health industries practice in India hit a double-digit compound annual growth rate in the past few years as well. But Ling Tok Hong, deals and private equity leader at PwC, cautioned that 'this continued focus on the India market could make it more susceptible to overvaluation if investors are not cautious'. South-east Asia's healthcare sector is also attracting PE investors, leading to 'unprecedented valuations' of Ebitda multiples in their 20s, noted Ling. He was referring to earnings before interest, taxes, depreciation and amortisation. Room for growth; returns still strong Despite the rising valuations in Asia's healthcare sector, market participants point out that there is still room for growth, a key factor backing the higher valuations in the first place. The sector offers attractive long-term growth prospects as the supply of quality healthcare assets in the region is not growing quickly enough to meet demand. In markets such as South-east Asia, 'the number of large, institutionally ready platforms is still limited. This scarcity has helped sustain high entry multiples in recent years', said Alex Boulton, partner and Asia-Pacific lead for healthcare and life sciences private equity at Bain. He pointed out that South-east Asia's healthcare sector relies heavily on private players. For instance, the private sector accounts for roughly half of all hospital beds in Indonesia and the Philippines. 'That structural dynamic creates an enduring role for private capital in expanding and upgrading healthcare infrastructure.' Market participants emphasise that Asian healthcare is not in bubble territory. Boulton pointed out that even with rising valuations, healthcare PE in Asia is still delivering strong returns. Bain's analysis shows that from 2018 to 2023, the median multiple on invested capital (MOIC) for exited healthcare deals in the region was approximately 2.6 – meaning that a US$1 million investment generated a return of US$2.6 million. This compares with the global median MOIC of around two. 'That speaks to the sector's ability to compound value through growth and operational improvement, even in a more expensive entry environment,' noted Boulton. That said, while returns are likely to remain strong in the future, the median MOIC may not be sustained at these levels, he added. Thus, market players said, investors will need to have a clear plan to create meaningful impact and value over the life of their investments.
